Adult: Clinical Trials

16 trials for Adult, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 4 recruiting, 1 active not recruiting, 1 not yet recruiting. 16 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 116Completed 10, Recruiting 4, Active not recruiting 1, Not yet recruiting 1
Phase 23Completed 3

Follow Adult: new trials by email Literature Review of Adult trials Research Report on Adult

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney Failure on Dialysis
Intravenous fosmanogepix - End Stage Renal Disease on Dialysis, Adult
Phase 1RecruitingBasilea Pharmaceutica202026-10-272026-11-04
PIN in Combination With Sintilimab in Previously Treated pMMR/MSS CRC With Hepatic Metastases
PIN+sintilimab - Colorectal Cancer, Adult
Phase 1Not yet recruitingChinese PLA General Hospital252026-03-012026-02-17
PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma
PIN +anti-PD1 - Hepatocellular Carcinoma, Adult
Phase 1RecruitingChinese PLA General Hospital252025-06-202025-06-22
PIN in Combination With Anti-PD1 in Previously Treated Solid Tumor
PIN +anti-PD1 - Solid Tumor, Adult
Phase 1RecruitingChinese PLA General Hospital252025-03-192025-06-10
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
KQB198, Dasatinib - Hematologic Malignancies, Adult
Phase 1Active not recruitingKumquat Biosciences Inc.132024-12-092026-03-25
IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma
IB-T101 injection - Advanced Clear Renal Cell Carcinoma, Adult
Phase 1RecruitingGrit Biotechnology122024-12-062026-04-14
A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants
Ritlecitinib - Healthy Volunteers, Adult
Phase 1CompletedPfizer122023-05-092024-10-16
Effect of Multiple Doses of Modafinil on the Pharmacokinetics of Single Dose Lorlatinib in Healthy Participants
Lorlatinib 50 mg, Lorlatinib 75 mg, Lorlatinib 100 mg - Adult, Drug Interactions
Phase 1CompletedPfizer162019-08-222020-01-18
Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells
INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS - SYSTEMIC SCLERODERMA, ALLOGENEIC MESENCHYMAL STEM CELLS
Phase 1 / Phase 2CompletedAssistance Publique - Hôpitaux de Paris202014-05-062024-05-01
Effects of Rapid-Resisted Exercise and Bright Light Therapy on Ambulatory Adults With Traumatic Brain Injury
Elliptical exercise - Adult, Traumatic Brain Injury
Phase 1 / Phase 2CompletedNational Institutes of Health Clinical Center (CC)342011-08-242026-10-16
Study Evaluating Single Ascending Doses of MR1817
MR1817, Placebo - Adult
Phase 1CompletedMochida Pharmaceutical Company, Ltd.642010-07-012014-01-13
Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)
Ertugliflozin 2 mg single dose, Ertugliflozin 2 mg split into twice daily, Ertugliflozin 4 mg single dose - Diabetes Mellitus, Type 2, Adult
Phase 1CompletedMerck Sharp & Dohme LLC522010-02-172019-11-21
Development and Evaluation of a Nursing Virtual Intervention Tailored for Pain After Cardiac Surgery
soulageTAVIE - Cardiac Surgery, Pain
Phase 1 / Phase 2CompletedCentre hospitalier de l'Université de Montréal (CHUM)602010-02-012010-09-15
Study Evaluating Effects of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG in Healthy Subjects
SAM-531, placebo, Donepezil - Healthy, Adult
Phase 1CompletedWyeth is now a wholly owned subsidiary of Pfizer252007-10-012008-04-22
Dose Ranging Study in Healthy Methadone Maintenance Subjects
MOA-728 - Adult
Phase 1CompletedBausch Health Americas, Inc.162006-06-012019-11-25
LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors
capecitabine, enzastaurin hydrochloride - Adult, Solid Tumor
Phase 1CompletedJonsson Comprehensive Cancer Center162002-12-012020-08-03

Narrower conditions

Agnosia (1)  ·  Alzheimer Disease (1)  ·  Brain Injuries, Traumatic (1)  ·  Carcinoma, Hepatocellular (1)  ·  Colorectal Neoplasms (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Hematologic Neoplasms (1)  ·  Pain (1)  ·  Pain, Postoperative (1)  ·  Scleroderma, Systemic (1)  ·  Stress Disorders, Post-Traumatic (1)

Broader conditions

Neoplasms (3)  ·  Neoplasms by Site (3)  ·  Nervous System Diseases (3)  ·  Brain Diseases (2)  ·  Central Nervous System Diseases (2)  ·  Digestive System Diseases (2)  ·  Digestive System Neoplasms (2)  ·  Mental Disorders (2)  ·  Adenocarcinoma (1)  ·  Brain Injuries (1)  ·  Carcinoma (1)  ·  Colonic Diseases (1)  ·  Connective Tissue Diseases (1)  ·  Craniocerebral Trauma (1)  ·  Dementia (1)

Interventions

Capecitabine (1)  ·  Dasatinib (1)  ·  Donepezil (1)  ·  PF-06651600 (1)  ·  SAM-531 (1)  ·  ertugliflozin (1)  ·  lorlatinib (1)

Sponsors

Chinese PLA General Hospital (3)  ·  Pfizer (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Basilea Pharmaceutica (1)  ·  Bausch Health Americas, Inc. (1)  ·  Centre hospitalier de l'Université de Montréal (CHUM) (1)  ·  Grit Biotechnology (1)  ·  Jonsson Comprehensive Cancer Center (1)  ·  Kumquat Biosciences Inc. (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Mochida Pharmaceutical Company, Ltd. (1)  ·  National Institutes of Health Clinical Center (CC) (1)  ·  Wyeth is now a wholly owned subsidiary of Pfizer (1)

Countries

United States (5)  ·  China (4)  ·  France (3)  ·  Belgium (2)  ·  United Kingdom (2)  ·  Canada (1)  ·  Germany (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Poland (1)  ·  Spain (1)

Top investigators

Lilin Ye, Ph.D (3)  ·  Weidong Han, Ph.D (3)  ·  Guanghua Rong, Ph.D (2)  ·  Zhijun Wang, M.D (2)  ·  Carolyn Britten, MD (1)  ·  Jeff Cohn (1)  ·  Robert Miller (1)  ·  Silvina G Horovitz, Ph.D. (1)  ·  Thomas Kaindl, MD (1)

Results publications

PMID 23241361, PMID 30802200, PMID 33937953, PMID 34213819, PMID 34623637, PMID 36928395

NIH funding

2019 (1)